Forging a global shield against HMPV: Uniting healthcare systems and community action to counter a silent respiratory epidemic.

Abstract

Background: Human metapneumovirus (HMPV) has emerged as a significant global cause of acute respiratory infections, disproportionately affecting vulnerable populations such as young children, the elderly, and immunocompromised individuals. Despite its considerable impact, contributing to 5%-15% of pediatric respiratory hospitalizations and 10% of respiratory deaths in children under five, HMPV often remains underdiagnosed and receives insufficient attention within public health frameworks. The absence of specific antiviral treatments and preventative vaccines further exacerbates its clinical consequences.

Aim: This review aims to consolidate current understanding regarding HMPV's epidemiology, clinical manifestations, diagnostic approaches, and management strategies, while also identifying existing gaps in prevention and research efforts.

Methods: A systematic review of peer-reviewed literature published between 2001 and 2024 was conducted. The search encompassed databases such as PubMed, Web of Science, and those maintained by the World Health Organization (WHO). Keywords utilized for the search included "human metapneumovirus", "HMPV epidemiology", and "HMPV treatment". Studies selected for inclusion were rigorously assessed for their epidemiological data, diagnostic methodologies, clinical management protocols, and preventative measures. The collected data were then synthesized to pinpoint critical knowledge deficiencies and areas requiring future research focus.

Results: Our comprehensive analysis indicates that HMPV contributes significantly to global morbidity, exhibiting seasonal patterns that vary geographically with hemisphere and climate. Diagnostic challenges persist due to the symptomatic overlap with other common respiratory viruses like RSV and influenza, and current treatment approaches remain primarily supportive. Promising advancements in vaccine development, including candidates targeting the F-protein and utilizing mRNA technology, are underway but necessitate further clinical evaluation. Populations at high risk, particularly those in resource-limited settings, experience a disproportionately higher burden of disease due to inadequate diagnostic capabilities and underdeveloped healthcare infrastructure.

Conclusions: HMPV represents a substantial, yet frequently underestimated, respiratory pathogen demanding immediate public health attention. Key priorities for addressing this include (1) the development of rapid and accessible diagnostic tools, (2) accelerating vaccine candidates through rigorous clinical trials, (3) establishing evidence-based treatment guidelines, and (4) strengthening global surveillance systems. A coordinated international effort is imperative to mitigate the considerable health and economic repercussions of HMPV infection.